Skip to main content

Market Overview

Bristol Myers' Psoriasis Med Deucravacitinib Superior To Amgen's Otezla, New Data Shows

Share:
Bristol Myers' Psoriasis Med Deucravacitinib Superior To Amgen's Otezla, New Data Shows
  • Bristol-Myers Squibb Co (NYSE: BMY) has announced new data from its two Phase 3 trials POETYK PSO-1 and POETYK PSO-2 for deucravacitinib, its oral, selective TYK2 inhibitor for moderate to severe plaque psoriasis.
  • Data were presented at the 2021 American Academy of Dermatology Virtual Meeting Experience.
  • In both pivotal studies, the psoriasis drug was superior to placebo and Amgen's Otezla, the current oral standard of care, including measures of durability and maintenance of response.
  • Specifically, deucravacitinib showed superior skin clearance compared with Otezla for key secondary endpoints, including PASI 75 and sPGA 0/1 responses at week 16, with an increased benefit versus Otezla at week 24 and maintained through week 52.
  • Additionally, deucravacitinib was superior to Otezla across both studies in multiple other secondary endpoints, demonstrating significant and clinically meaningful efficacy improvements in symptom burden and quality of life measures.
  • Price Action: BMY shares are up 0.06% at $66.35 in market hours on the last check Friday.
 

Related Articles (AMGN + BMY)

View Comments and Join the Discussion!

Posted-In: Briefs PsoriasisBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com